Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression

Autor: Pugazhenthi Umarani, Loi Michele, Hays William R, Berenz Andrew, Sharma Vibha, Klopper Joshua P, Said Sherif, Haugen Bryan R

Publikováno v: Molecular Cancer, Vol 8, Iss 1, p 16 (2009)

Abstract Background Metastatic melanoma has a high mortality rate and suboptimal therapeutic options. Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid × receptor selective agonist, and thiazolidinediones (TZD), PPARγ sel

Externí odkaz: https://doaj.org/article/1b3920c7528944c6955d051e7be0e72d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis.

Autor: Sharma V; Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver and Health Sciences Center, MS 8106, P.O. Box 6511, Aurora, Colorado 80045, USA., Hays WR, Wood WM, Pugazhenthi U, St Germain DL, Bianco AC, Krezel W, Chambon P, Haugen BR

Publikováno v: Endocrinology [Endocrinology] 2006 Mar; Vol. 147 (3), pp. 1438-51. Date of Electronic Publication: 2005 Nov 23.

Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment.

Autor: Klopper JP; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Box B151, 4200 East 9th Avenue, Denver, CO 80262, USA. joshua.klopper@uchsc.edu, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2004 Aug; Vol. 3 (8), pp. 1011-20.